Miguel Garcia-Caro, MD
Rheumatology · Alexandria, LANPI 1508859455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 696 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Amgen at 40.7% of the total. Reporting peaked in 2020 at $3,041 and has fallen 59.8% since, to $1,222 in 2025.
Across 696 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Johnson & Johnson$1K
- Pfizer$929
- Mallinckrodt Hospital Products Inc.$744
- GSK$638
- E.r. Squibb & Sons, L.L.C.$532
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$1,2009%
- Food & beverage$12,27591%
- Education$670%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 204 | $5,514 |
| Johnson & Johnson | 83 | $1,480 |
| Pfizer | 60 | $929 |
| Mallinckrodt Hospital Products Inc. | 39 | $744 |
| GSK | 38 | $638 |
| E.r. Squibb & Sons, L.L.C. | 56 | $532 |
| ANI Pharmaceuticals, Inc. | 21 | $501 |
| Novartis | 20 | $402 |
| Regeneron Healthcare Solutions, Inc. | 15 | $270 |
| AbbVie(2 entities) | 10 | $262 |
| Medexus Pharma, Inc. | 32 | $262 |
| UCB, Inc. | 14 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $219 |
| AstraZeneca | 14 | $214 |
| Lilly USA, LLC | 11 | $161 |
| Mallinckrodt Enterprises LLC | 10 | $159 |
| Galderma Laboratories, L.p. | 8 | $151 |
| Genentech USA, Inc. | 9 | $148 |
| Boehringer Ingelheim | 5 | $118 |
| Aurinia Pharma U.S., Inc. | 7 | $117 |
| Sanofi | 8 | $113 |
| Zyla Life Sciences, Inc. | 3 | $56 |
| Antares Pharma, Inc. | 3 | $47 |
| Eisai Inc. | 3 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Hikma Pharmaceuticals USA | 2 | $31 |
| Medtronic | 1 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,541 in reported general payments places this provider in the 60th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 16 | $1,357,235 |
| Humira(Cf) PenAdalimumab | 89 | $724,231 |
| OrenciaAbatacept/Maltose | 146 | $653,049 |
| Enbrel SureclickEtanercept | 47 | $368,925 |
| BenlystaBelimumab | 60 | $257,927 |
| Xeljanz XrTofacitinib Citrate | 38 | $235,600 |
| ActemraTocilizumab | 73 | $235,556 |
| OtezlaApremilast | 48 | $231,992 |
| Simponi AriaGolimumab | 27 | $200,900 |
| SimponiGolimumab | 32 | $200,044 |
| EnbrelEtanercept | 25 | $180,157 |
| Cimzia (2 Pack)Certolizumab Pegol | 28 | $160,849 |
| RinvoqUpadacitinib | 20 | $138,116 |
| Actemra ActpenTocilizumab | 27 | $119,335 |
| Humira PenAdalimumab | 15 | $105,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $744 | $1,357,23516 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $532 | $724,308159 claims |
| Johnson & JohnsonSimponi Aria, Simponi, Remicade | $1,480 | $502,18085 claims |
| AmgenOtezla, Enbrel, Prolia | $5,514 | $430,77284 claims |
| GSKBenlysta, Trelegy Ellipta | $638 | $266,15273 claims |
| AbbVieRinvoq, Vraylar, Linzess | $262 | $169,41847 claims |
| UCB, Inc.Cimzia (2 Pack) | $249 | $160,84928 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $34 | $35,79741 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $219 | $12,87027 claims |
| Medexus Pharma, Inc.Rasuvo | $262 | $9,91218 claims |
| Antares Pharma, Inc.Otrexup | $47 | $8,11911 claims |
| Hikma Pharmaceuticals USAMitigare | $31 | $7,69820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Alexandria
- Agnes SolonAlexandria$123K
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
- Carl GauthierHammond$219K
- Malik SpadyCovington$160K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Randall BeylBaton Rouge$112K
- Frankie PedigoShreveport$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.